Jesduvroq Approved for Anemia of CKD in Patients on Dialysis
Daprodustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor.
Daprodustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor.
Enjaymo is an immunoglobulin G subclass 4 monoclonal antibody.
Cognitive scores were lower in iron-deficient children after intervention, despite improvement in serum ferritin
Investigators compared the therapies in a large national cohort of patients with normal kidney function.
The table provided is a review of notable updates that occurred in October 2022 for investigational products in development.
Approvals for relapsed or refractory multiple myeloma, non-radiographic axial spondyloarthritis, and unresectable hepatocellular carcinoma; advisory committee takes vote on potential treatment for anemia of chronic kidney disease; and an oral formulation of pulmonary arterial hypertension treatment.
The NDA was supported by data from the ASCEND clinical program, which included dialysis and nondialysis patients.
Zynteglo is a one-time gene therapy that works by adding functional copies of a modified form of the β-globin gene into a patient’s own hematopoietic stem cells.
KP104 is a bifunctional, first-in-class biologic that works by selectively inhibiting the alternative and terminal pathways in the complement system.
Beti-cel is an investigational one-time gene therapy that works by adding functional copies of a modified form of the beta-globin gene into a patient’s own hematopoietic stem cells.